CD19-CD22 CAR-T cells is under clinical development by Shanghai Biomed-Union Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas.

The therapeutic candidate is under development for the treatment of ovarian cancer. It comprises of induced pluripotent stem (iPS) cell derived natural killer (iNK) cell.

Anti-CDH17 CAR-T Cells is under clinical development by UTC Therapeutics and currently in Phase I for Pancreatic Cancer.

Coronavirus Disease 2019 (SARS-CoV-2) vaccine is under clinical development by Shionogi and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

HM-0021005 ER is under clinical development by Hua Medicine Shanghai and currently in Phase I for Type 2 Diabetes.

NUV-868 is under clinical development by Nuvation Bio and currently in Phase II for Triple-Negative Breast Cancer (TNBC).

QL-401 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Relapsed Acute Myeloid Leukemia.

NA-731 is under clinical development by Biomed Industries and currently in Phase I for Traumatic Brain Injury.

Alphaf-001 is under clinical development by Alpha Fusion and currently in Phase I for Follicular Thyroid Cancer.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Vebeglogene autotemcel is under clinical development by Lantu Biopharma and currently in Phase II for Beta Thalassaemia.